Healthcare Analysts, along with Dr. Yaacov Anziske of SUNY Downstate, discuss Sarepta’s (SRPT) ELEVIDYS and the future of Duchenne Muscular Dystrophy (DMD) on an Analyst/Industry conference call to be held on April 4 at 10 am.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta sinks 9% after Elevidys studies placed on hold in Europe
- Sarepta price target lowered to $183 from $202 at Needham
- Sarepta study pause brings approvability risk in Europe, says RBC
- Sarepta clinical hold in Europe likely temporary, says Mizuho
- EMA put clinical hold on Roche, Sarepta DMD studies after death